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Supplementary Table 
Supplementary Table 1 L-BLP25 Clinical Trials
Protocol 
number
Population
Start date
Status
Description Subjects Treatment Schedule for L-BLP25 
Vaccinations
a
Enrolled Treated 
with 
L-BLP25
Primary 
Treatment
Maintenance 
Treatment
Dose Weeks Dose Interval
b
NSCLC Trials
EMR 63325-
002
Stage IIIB or 
IV NSCLC
04 Aug 1998
Trial closed 
17 Nov 2005
Phase I open-label 
safety & dose-
comparison trial
17 16 20 or 
200 μg
0,2,5,9 20 or 
200 
μg
Every 12 
weeks 
EMR 63325-
003 
Stage IIIB or 
IV NSCLC
06 Aug 1999
Trial closed 
10 Dec 2004
Phase II open-label 
safety & 
immunogenicity 
trial
9 8 1000 μg Weekly 
x 8
250 
μg
Every 6 
weeks 
EMR 63325-
004
Stage IIIB or 
IV NSCLC
24 Jan 2000
Trial closed 
12 Dec 2005
Phase II open-label 
dose-escalation 
trial to determine 
safety & 
immunogenicity of 
L-BLP25 in 
combination with 
L-IL-2
18 18 1000 μg 
combine
d with 
5 x 10
5 or 
2 x 10
6 IU 
L-IL-2
Weekly 
x 8
250 
μg
Every 6 
weeks 
EMR 63325-
005
Stage IIIB or 
IV NSCLC
08 Aug 2000
Closed to 
enrollment
Phase IIb open-
label randomized 
trial to test safety & 
efficacy of 
L-BLP25 plus best 
supportive care 
(BSC) compared to 
BSC alone
171 88 930 μg Weekly 
x 8
930 
μg
Every 6 
weeks 
EMR 63325-
006
Unresected 
stage III 
NSCLC
18 Apr 2005
Closed to 
enrollment
Phase II open-label 
trial to assess 
safety of L-BLP25 
made with 
immunoadjuvant 
MPL
® from GSK 
Biologicals North 
America
22 22 930 μg Weekly 
x 8
930 
μg
Every 6 
weeks 
EMR 63325-
001 
Unresectabl
e stage III 
NSCLC
22 Feb 2007
Open to 
enrollment 
“START” trial. 
Phase III 
randomized, 
double-blind, 
placebo-controlled 
trial to test safety & 
efficacy of 
L-BLP25 plus BSC 
compared to BSC 
alone
1273
c Blinded 930 μg Weekly 
x 8
930 
μg
Every 6 
weeks Protocol 
number
Population
Start date
Status
Description Subjects Treatment Schedule for L-BLP25 
Vaccinations
a
Enrolled Treated 
with 
L-BLP25
Primary 
Treatment
Maintenance 
Treatment
Dose Weeks Dose Interval
b
EMR 63325-
009 
Unresectabl
e stage III 
NSCLC
12 Feb 2009 
(Step 1) 
Combined phase I/
II trial of L-BLP25 
in Japanese 
subjects with stage 
III unresectable 
NSCLC following 
primary chemo-
radio-therapy
7 6 930 μg Weekly 
x 8
930 
μg
Every 6 
weeks 
EMR 63325-
012 
(“INSPIRE”)
Unresected 
stage III 
NSCLC
02 Dec 2009 
Open to 
enrolment
Phase III 
randomized, 
double-blind, 
placebo-controlled 
trial to test safety 
&efficacy of 
L-BLP25 plus BSC 
compared to 
Placebo plus BSC 
in Asian patients
8
c Blinded  930 μg Weekly 
x 8
930 
μg
Every 6 
weeks 
Other Trials
EMR 63325-
007
Prostate 
cancer
26 Oct 2001
Trial closed 
07 Jan 2005
Phase II open-label 
trial to test safety & 
efficacy of 
L-BLP25 in 
subjects with rising 
prostate-specific 
antigen values 
following radical 
prostatectomy
16 16 1000 μg Weekly 
x 8
1000 
μg
Every 6 
weeks 
EMR 63325-
008 
Multiple 
myeloma
21 Jan 2008
Open to 
enrollment
Phase II 
randomized, open-
label trial to test 
safety & efficacy of 
L-BLP25 in 
combination with 
one or more 
administrations of 
cyclophosphamide
b
34
c 34
c 930 μg Weekly 
x 8
930 
μg
Every 6 
weeks Protocol 
number
Population
Start date
Status
Description Subjects Treatment Schedule for L-BLP25 
Vaccinations
a
Enrolled Treated 
with 
L-BLP25
Primary 
Treatment
Maintenance 
Treatment
Dose Weeks Dose Interval
b
EMR 
200038-010 
(“STRIDE”)
Breast 
Cancer 
20 Oct 2009
Trial 
terminated 
July 2010
Phase III 
randomized 
double-blind, 
placebo-controlled 
trial to test 
L-BLP25 in 
combination with 
hormonal 
treatment versus 
hormonal 
treatment alone for 
first-line therapy of 
post-menopausal 
women with 
estrogen receptor 
(ER)-positive 
and/or 
progesterone 
receptor (PgR)-
positive, inoperable 
locally advanced, 
recurrent, or 
metastatic breast 
cancer
16
c Blinded 930 μg Weekly 
x 8
930 
μg
Every 6 
weeks 